Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$36.28

-1.01 (-2.71%)

11:00
11/29/16
11/29
11:00
11/29/16
11:00

Baird sees strong launch for Sarepta after surveying neurologists

After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.

SRPT Sarepta
$36.28

-1.01 (-2.71%)

10/27/16
PIPR
10/27/16
NO CHANGE
PIPR
Overweight
Piper cuts sales estimates for Sarepta's Exondys51
After management of Sarepta Therapeutics guided that reimbursement typically takes 30-90 days, Piper Jaffray analyst Edward Tenthoff cut his U.S. Exondys51 forecast to $4.5M from $21.5M in Q4 and to $274M from $330M in 2017. The analyst continues to project peak U.S. sales of greater than $500M. He reiterates an Overweight rating on shares of Sarepta with a $68 price atregt following the company's Q3 results. The stock is down 9%, or $3.84, to $40.70 in afternoon trading.
10/27/16
FBCO
10/27/16
NO CHANGE
Target $68
FBCO
Outperform
Sarepta reimbursement concerns overdone, says Credit Suisse
Credit Suisse analyst Alethia Young believes Sarepta Exondys 51 reimbursement concerns are "quite overdone" and notes payer negotiation is inline with what the company has seen in other rare disease drugs launch. Young rates Sarepta an Outperform with a $68 price target.
10/27/16
WEDB
10/27/16
NO CHANGE
Target $72
WEDB
Outperform
Sarepta selloff overdone, says Wedbush
Wedbush analyst Heather Behanna said the selloff in Sarepta is overdone and recommends shares ahead of the Exondys 51 launch update in January. The analyst has an Outperform rating and a $72 price target on Sarepta shares.
11/11/16
LEER
11/11/16
NO CHANGE
Target $55
LEER
Market Perform
Sarepta Exondys 51 launch expectations seem too high for 2017, says Leerink
Leerink analyst Joseph Schwartz believes Sarepta Exondys 51 launch expectations may be too high for 2017. While nothing that a true Duchenne muscular dystrophy prevalence remains unknown, the analyst says that a "start form" number of about 200 patients would need to be provided in early January in order for investors to be confident in 2017 consensus sales estimates of $215M. Additionally, Schwartz points out that based on the price of Exondys 51 per vial, it currently appears that management has underestimated the true price of the drug which they will realize.

TODAY'S FREE FLY STORIES

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

, YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

12:03
02/24/17
02/24
12:03
02/24/17
12:03
Periodicals
Federal Reserve clears F.N.B.'s takeover of Yadkin, Reuters reports »

The Federal Reserve has…

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

12:01
02/24/17
02/24
12:01
02/24/17
12:01
Options
Heavy trading in Nvidia short-term options as shares stage an aggressive rebound »

Heavy trading in Nvidia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

12:00
02/24/17
02/24
12:00
02/24/17
12:00
General news
Treasury Option Action: a round of put activity »

Treasury Option Action: a…

ONCS

OncoSec

$1.42

-0.1 (-6.58%)

11:59
02/24/17
02/24
11:59
02/24/17
11:59
Conference/Events
OncoSec to hold KOL Event Focused on New ASCO-SITC Melanoma Data »

OncoSec's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$13.99

-0.06 (-0.43%)

11:55
02/24/17
02/24
11:55
02/24/17
11:55
Hot Stocks
Boulder Ventures V reports 9.9% stake in Miragen Therapeutics »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTG

MGIC Investment

$10.55

-0.055 (-0.52%)

11:51
02/24/17
02/24
11:51
02/24/17
11:51
Options
MGIC Investment with 11.5X average daily optoin volume driven by a bullish play »

MGIC Investment with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$11.06

-0.09 (-0.81%)

11:46
02/24/17
02/24
11:46
02/24/17
11:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

11:45
02/24/17
02/24
11:45
02/24/17
11:45
Conference/Events
Leerink analysts hold an analyst/industry conference call »

In conjunction with the…

11:40
02/24/17
02/24
11:40
02/24/17
11:40
General news
NY Fed Nowcast has Q1 GDP at 3.12% »

NY Fed Nowcast has Q1 GDP…

SPWR

SunPower

$8.99

0.53 (6.26%)

11:36
02/24/17
02/24
11:36
02/24/17
11:36
Options
SunPower put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.05 (2.98%)

11:33
02/24/17
02/24
11:33
02/24/17
11:33
Hot Stocks
Idera says achieved 'successful' completion of objectives in Phase 1 trial »

Idera Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$5.90

-0.1 (-1.67%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Trillium Therapeutics: New TTI-621 data advances understanding of product »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

, CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Volt Information Sciences reports nomination of new independent directors »

Volt Information Sciences…

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 14

    Mar

  • 21

    Mar

MCO

Moody's

$112.59

-0.64 (-0.57%)

11:31
02/24/17
02/24
11:31
02/24/17
11:31
Conference/Events
Leerink analysts hold an analyst/industry conference call »

Analysts provide a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

, MDIUY

Mediaset

11:28
02/24/17
02/24
11:28
02/24/17
11:28
Periodicals
Milan prosecutors investigating Vivendi over alleged stock manipulation, FT says »

Milan prosecutors are…

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

MDIUY

Mediaset

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$37.19

3.62 (10.78%)

11:26
02/24/17
02/24
11:26
02/24/17
11:26
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

GS

Goldman Sachs

$247.19

-4 (-1.59%)

11:23
02/24/17
02/24
11:23
02/24/17
11:23
Periodicals
Goldman Sachs exec involved in 1MDB dealings leaves bank, WSJ says »

A senior Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

ALNY

Alnylam

$46.25

0.3 (0.65%)

11:22
02/24/17
02/24
11:22
02/24/17
11:22
Conference/Events
JPMorgan SMid biotech analyst holds an analyst/industry conference call »

SMid Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

$NSD

NASDAQ Market Internals

11:17
02/24/17
02/24
11:17
02/24/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBLY

Mobileye

$46.96

-1.18 (-2.45%)

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Options
Mobileye put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HBI

Hanesbrands

$20.96

0.04 (0.19%)

11:12
02/24/17
02/24
11:12
02/24/17
11:12
Conference/Events
Hanesbrands management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

WIX

Wix.com

$63.25

-2.3 (-3.51%)

11:10
02/24/17
02/24
11:10
02/24/17
11:10
Conference/Events
Wix.com management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SNCR

Synchronoss

$30.86

-0.03 (-0.10%)

11:09
02/24/17
02/24
11:09
02/24/17
11:09
Periodicals
Synchronoss has withheld 'a great deal' about 'transformation,' SIRF says »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXN

Rexnord

$22.05

-0.09 (-0.41%)

11:08
02/24/17
02/24
11:08
02/24/17
11:08
Conference/Events
Rexnord management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.